Zobrazeno 1 - 10
of 365
pro vyhledávání: '"J. Fraisse"'
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Classical phase 1 dose-finding designs based on a single toxicity endpoint to assess the maximum tolerated dose were initially developed in the context of cytotoxic drugs. With the emergence of molecular targeted agents and immuno
Externí odkaz:
https://doaj.org/article/3a071f68e9164ced9e5f4a1103f5f284
Autor:
D. Dinart, J. Fraisse, D. Tosi, A. Mauguen, C. Touraine, S. Gourgou, M. C. Le Deley, C. Bellera, C. Mollevi
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Severa
Externí odkaz:
https://doaj.org/article/7a047fe166cf4466945a8c5fa9d106bd
Autor:
P. Sargos, S. Guerif, J. Fraisse, E. Meyer, S. Supiot, E. Lagneau, E. Deniaud-Alexandre, P. Rochin, A. Benyoucef, L. Cartier, H. Hamidou, A. Hasbini, G. Crehange, P. Pommier, G. De Laroche, S. Pelissier, E. Gross, P. Fourneret, L. Salomon, I. Latorzeff
Publikováno v:
European Urology Open Science, Vol 19, Iss , Pp e1398-e1399 (2020)
Externí odkaz:
https://doaj.org/article/922f6038a96a4d479fbd8fadf4da8eee
Publikováno v:
Annales de Chirurgie Plastique Esthétique. 67:105-110
Extravasation of chemotherapeutic agents is a common complication in cancer centers. In severe cases involving large tissue necrosis, surgery may be needed to resect necrotic tissues and to cover the exposed areas.A 71 years old women was referred to
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Leila Bengrine, François Ghiringhelli, Julie Vincent, David Orry, Audrey Hennequin, J. Fraisse, Valeria Basso
Publikováno v:
World Journal of Gastrointestinal Oncology
BACKGROUND Triplet chemotherapy, with docetaxel-5FU-oxaliplatin FLOT regimen recently became the standard perioperative treatment for localized gastric cancer (GC). An adapted regimen called TeFOX was recently tested in metastatic setting and gave pr
Additional file 1 Supplementary material 1. References of the 22 reviewed articles “With OBD”. Supplementary material 2. References of the 15 reviewed articles “Without OBD”. Supplementary material 3. Prisma Checklist.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01863b026c0ba07a0e172ab3bf4b2140
Autor:
D. Dinart, J. Fraisse, D. Tosi, A. Mauguen, C. Touraine, S. Gourgou, M. C. Le Deley, C. Bellera, Mollevi, C.
Additional file 1: Figure 1. Implementation of GUIP1 (a) CRML, (b) TITE-CRM, (c) EWOC, and (d) TITE-EWOC (motivating example).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be5ee5c6f4d69f90d59ca5bdef73c9c
Autor:
Corinne Frere, L. Buscail, Cindy Canivet, Barbara Bournet, S. Gourgou, J. Fraisse, Jean M. Connors, Dominique Farge
Publikováno v:
Thrombosis Research. 200:S4
Autor:
S. Pelissier, Stéphane Guerif, I. Latorzeff, Philippe Ronchin, Nicolas Magné, Elisabeth Deniaud-Alexandre, P. Pommier, Hadji Hamidou, Stéphane Supiot, A. Benyoucef, L. Cartier, Ali Hasbini, Laurent Salomon, E. Meyer, E. Gross, E. Lagneau, P. Fourneret, Paul Sargos, Gilles Créhange, J. Fraisse
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 105:S134